Timothy Barberich retires as Chair; Stephen Biggar, M.D., Ph.D. assumes the role of Chair Mr. Nicholson has more than 35 years of pharmaceutical and biotech oncology experience. Mr. Nicholson currently serves as chairman of the board of directors for G1 Therapeutics, Day One Biopharmaceuticals and Abdera Therapeutics. He also previously served on the board of directors for Turning Point Therapeutics, Five Prime Therapeutics, Tmunity and TESARO prior to their acquisitions by large pharmaceutical companies. A ...

Timothy Barberich retires as Chair; Stephen Biggar, M.D., Ph.D. assumes the role of Chair "We are pleased to welcome Garry to our Board of Directors. He has a breadth of experience in oncology development and commercialization spanning more than 35 years, including serving as president of Pfizer Oncology where he led its global oncology franchise," said Gavin MacBeath, Ph.D., Chief Executive Officer. "Garry has extensive expertise in operations, sales, regulatory strategy, and commercialization, and we look ...

WALTHAM, Mass, May 29, 2024 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage biopharmaceutical company focused on the development of T cell receptor (TCR)-engineered T cell (TCR-T) therapies for the treatment of patients with cancer, today announced that the U.S. Food and Drug Administration (FDA) has granted Regenerative Medicine Advanced Therapy (RMAT) designation to TSC-100 and TSC-101, the Company's two lead TCR-T therapy candidates for the treatment of heme malignancies (NC ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 | For the transition period from _____________________________to_____________________________________________________ | | | --- | --- | | Commission File Number: 001-40603 | | | TSCAN THERA ...

Exhibit 99.1 TScan Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate Update First patient dosed in Phase 1 clinical trial for the treatment of solid tumors; initial data anticipated in 2024 All treatment-arm patients in the Phase 1 heme program remain relapse-free with no detectable disease, with a median follow-up of >10 months Closed upsized underwritten public offering with gross proceeds of $167.8 million, extending runway into the fourth quarter of 2026 WALTHAM, Mass., Ma ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 (Exact name of Registrant as specified in its Charter) Delaware 82-5282075 (State or other jurisdiction of incorporation or organization) 830 Winter Street Waltham, Massachusetts 02451 (Address of principal executive offices) (Zip Code) For the fiscal year ended December 31, 2023 OR ☐ TRANSITION REPORT PURSUANT T ...

[TScan Therapeutics Fourth Quarter and Full Year 2023 Business Update and Financial Results](index=1&type=section&id=TScan%20Therapeutics%20Fourth%20Quarter%20and%20Full%20Year%202023%20Business%20Update%20and%20Financial%20Results) [Business and Clinical Highlights](index=1&type=section&id=Business%20and%20Clinical%20Highlights) TScan Therapeutics advanced clinical programs, with all eight heme malignancy patients relapse-free and two new INDs cleared for solid tumors - In the ongoing Phase 1 study for heme malignancies, **all 8 patients** in the TSC-100 and TSC-101 treatment arms are **relapse-free** and show **complete donor chimerism**[1](index=1&type=chunk) - The FDA cleared **two additional Investigational New Drug (IND) applications** for the Solid Tumor Program: TSC-201-B0702 (targeting MAGE-C2) and TSC-204-A0101 (targeting MAGE-A1)[1](index=1&type=chunk)[5](index=5&type=chunk) - The company is on track to treat the **first patient in its Phase 1 solid tumor program in March 2024**, with **initial data from singleplex and multiplex cohorts expected in 2024**[2](index=2&type=chunk) - A high-risk TP53-mutated MDS patient reached the **one-year relapse-free milestone**, a significant indicator of long-term positive outcomes[2](index=2&type=chunk)[5](index=5&type=chunk) [Clinical Program Updates and Outlook](index=2&type=section&id=Clinical%20Program%20Updates%20and%20Outlook) The company provided updates on its heme malignancies program, showing promising efficacy, and its advancing solid tumor program [Hematologic Malignancies Program (TSC-100 & TSC-101)](index=2&type=section&id=Hematologic%20Malignancies%20Program%20(TSC-100%20%26%20TSC-101)) The Phase 1 trial for TSC-100 and TSC-101 shows strong results, with all eight treatment-arm patients relapse-free - **All eight (100%) treatment-arm patients were free from relapse**, with four patients having follow-up beyond ten months, indicating **complete elimination of target cells**[5](index=5&type=chunk) - **Two of six patients in the control arm relapsed**, and a third required clinical intervention due to concerns of impending relapse[5](index=5&type=chunk) - Upcoming Milestones: **Complete Phase 1 enrollment and report one-year data in 2024**; **initiate registration trial and report two-year relapse data in 2025**[13](index=13&type=chunk) [Solid Tumor Program (ImmunoBank)](index=2&type=section&id=Solid%20Tumor%20Program%20(ImmunoBank)) The solid tumor program is rapidly advancing with six TCR-Ts cleared for clinical development, with first patient dosing in Q1 2024 - TScan now has **six enhanced TCR-Ts cleared for clinical development**, expanding its ImmunoBank of therapeutic TCRs[4](index=4&type=chunk)[5](index=5&type=chunk) - The **first patient in the Phase 1 solid tumor study is expected to be dosed in Q1 2024**[4](index=4&type=chunk)[13](index=13&type=chunk) - Upcoming Milestones: **Share initial data from singleplex and multiplex cohorts in 2024**; **continue filing additional INDs throughout 2024**; **anticipate long-term duration of response data in 2025**[13](index=13&type=chunk) [Management and Corporate Developments](index=2&type=section&id=Management%20and%20Corporate%20Developments) TScan strengthened its leadership team with key appointments and promotions, and received 'Top Place to Work' recognition - Appointed **Jason A. Amello as Chief Financial Officer** and **Justin McCue, Ph.D., as Chief Technology Officer**[6](index=6&type=chunk) - Promoted **Zoran Zdraveski, J.D., Ph.D., to Chief Legal and Strategy Officer**, **Cagan Gurer, Ph.D., to SVP, Discovery**, and **Jim Murray to SVP, Head of Development Operations**[6](index=6&type=chunk)[13](index=13&type=chunk) - For the second year in a row, the company was **named a Top Place to Work by The Boston Globe** in November 2023[13](index=13&type=chunk) [Financial Performance](index=3&type=section&id=Financial%20Performance) TScan reported **full-year 2023 revenue of $21.0 million**, a **net loss of $89.2 million**, and a **$192.0 million cash position** [Financial Results Summary (Q4 and Full Year 2023)](index=3&type=section&id=Financial%20Results%20Summary%20(Q4%20and%20Full%20Year%202023)) Revenue increased in Q4 and full-year 2023 due to the Amgen collaboration, but higher expenses led to a wider net loss Financial Results Summary (Q4 and Full Year 2023) (Millions USD) | Financial Metric | Q4 2023 | Q4 2022 | Full Year 2023 | Full Year 2022 | | :--- | :--- | :--- | :--- | :--- | | **Revenue** | $7.2M | $3.1M | $21.0M | $13.5M | | **R&D Expenses** | $22.4M | $15.6M | $88.2M | $59.8M | | **G&A Expenses** | $6.2M | $6.1M | $26.4M | $20.4M | | **Net Loss** | ($19.6M) | ($18.7M) | ($89.2M) | ($66.2M) | - The increase in revenue is primarily due to the timing of research activities related to the **Amgen collaboration**, which commenced in May 2023[9](index=9&type=chunk) - As of December 31, 2023, cash, cash equivalents, and marketable securities were **$192.0 million**, which is expected to **fund the current operating plan into 2026**[14](index=14&type=chunk) [Condensed Consolidated Balance Sheet](index=5&type=section&id=Condensed%20Consolidated%20Balance%20Sheet) As of December 31, 2023, TScan's **total assets grew to $272.1 million**, with **cash increasing to $192.0 million** Condensed Consolidated Balance Sheet (Thousands USD) | (in thousands) | December 31, 2023 | December 31, 2022 | | :--- | :--- | :--- | | **Cash, cash equivalents, and marketable securities** | $192,044 | $120,027 | | **Total assets** | $272,149 | $199,091 | | **Total liabilities** | $121,282 | $99,657 | | **Total stockholders' equity** | $150,867 | $99,434 | [Condensed Consolidated Statements of Operations](index=6&type=section&id=Condensed%20Consolidated%20Statements%20of%20Operations) For 2023, TScan reported **collaboration revenue of $21.0 million**, **total operating expenses of $114.5 million**, and a **net loss of $89.2 million** Condensed Consolidated Statements of Operations (Thousands USD, except per share amounts) | (in thousands, except per share amounts) | Twelve Months Ended Dec 31, 2023 | Twelve Months Ended Dec 31, 2022 | | :--- | :--- | :--- | | **Collaboration and license revenue** | $21,049 | $13,535 | | **Total operating expenses** | $114,507 | $80,171 | | **Loss from operations** | ($93,458) | ($66,636) | | **Net loss** | ($89,218) | ($66,221) | | **Net loss per share, basic and diluted** | ($1.36) | ($2.75) |

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _____________________________to_____________________________________________________ Commission File Number: 001-40603 TSCAN THERAPEUTICS, INC. (Exact nam ...

1 This presentation and the accompanying discussion contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, express or implied statements regarding the Company's plans, progress, and timing relating to the Company's solid tumor programs and the presentation of data, the Company's current and future research and development plans or expectations, the structure, timing and success of the Company's planned preclinical develop ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _____________________________to_____________________________________________________ Commission File Number: 001-40603 TSCAN THERAPEUTICS, INC. (Exact name of ...